Tissue-directed antibodies and methods of using the same
US-2024342260-A1 · Oct 17, 2024 · US
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US2025066501A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025066501-A1 |
| Application number | US-202418825958-A |
| Country | US |
| Kind code | A1 |
| Filing date | Sep 5, 2024 |
| Priority date | Jun 24, 2015 |
| Publication date | Feb 27, 2025 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
First claim
Opening claim text (preview).
We claim: 1 . A method of suppressing activity of an immune suppressor cell, comprising contacting the immune suppressor cell with an antibody that specifically binds CD38.
Assignees
Inventors
Classifications
substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title
characterised by the host/recipient, e.g. newborn with maternal antibodies · CPC title
characterised by the dose, timing or administration schedule · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2025066501A1 cover?
- The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2896. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Feb 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).